The risk of deep fungal infections during biologic therapy for psoriasis

Authors

Errata

This article is corrected by:

  1. Errata: Erratum Volume 29, Issue 1, 193–194, Article first published online: 22 December 2014

  • Conflicts of interest

      Conflicts of interest
    • Dr. Wu received research funding from Abbott Laboratories, AbbVie, Amgen, Eli Lilly, Merck, and Pfizer, which were not directly related to this manuscript. The other authors do not have any potential conflicts of interest.
  • Funding sources

      Funding sources
    • None declared.

Abstract

With a growing understanding of the pathogenesis and immunological basis of psoriasis, the medical community has seen the development of more focused biological treatment options for patients suffering from the disease, which are beginning to revolutionize the treatment of psoriasis. It is already well known that certain biologics are associated with an increased risk of reactivating tuberculosis in patients with latent disease, however, with increasing use of biologic agents across indications, there has also been a rise in reports of associated deep fungal infections. The mechanism of action of these biologic anti-psoriatic therapies allows physicians to address the underlying cause of patients' symptoms. The question though, is whether this same therapeutic mechanism may predispose patients to serious infections, including deep fungal infections.

Ancillary